Safety and Efficacy of Chronic Therapy with Captopril in Hypertensive Patients: An Update

Journal of Clinical Pharmacology - Tập 21 Số 11 - Trang 508-516 - 1981
Bernard Waeber1, Haralambos Gavras1, Hans R. Brunner1
1Department of Medicine and the Thorndike Memorial Research Laboratories, Boston University Medical Center, Boston, Mass., and the Department of Medicine, Centre Hospitalier Universitaire, Lausanne, Switzerland.

Tóm tắt

Abstract: Captopril, an orally active angiotensin‐converting enzyme inhibitor, has been administered to 81 patients with different types of clinical hypertension. Most of the patients had previously uncontrollable high blood pressure. In order to achieve a satisfactory blood pressure control during long‐term captopril therapy, a concomitant decrease in total body sodium was required in more than half of the patients. During our first two years of clinical experience with this new antihypertensive agent, side effects developed in 46.9 per cent of the patients and necessitated the withdrawal of the drug in 23.4 per cent of all patients. Only a few side effects such as hypotensive or syncopal episodes and cold extremities appeared to be due to the chronic blockade of the renin‐angiotensin system. The most frequent and the most serious adverse reactions such as skin rash, altered taste, pancytopenia, and pemphigus foliaceus seemed to be specifically drug related. The incidence of cutaneous and taste problems was markedly higher in patients with impaired renal function in whom retention of captopril has been previously demonstrated. This suggests that the occurrence of adverse reactions to captopril could be lowered in the future by using smaller daily doses and by titrating them according to the renal function.

Từ khóa


Tài liệu tham khảo

10.1056/NEJM197805042981803

10.7326/0003-4819-90-1-19

Wauters JP, 1979, Captopril and salt subtraction to treat “uncontrollable” hypertension in hemodialysis patients, Proc Eur Dialysis and Transplant Assoc., 16, 610

10.7326/0003-4819-94-1-58

Brunner HR, 1976, Angiotensin II blockade in normal man and patients with essential hypertension, Prog Biochem Pharmacol., 12, 145

Gavras H, 1978, Redistribution of regional blood flow after inhibition of the angiotensin‐converting enzyme, Circ Res. (Suppl. 1), 43, I‐59

Cody RJ, 1978, Haemodynamics of orally‐active converting enzyme inhibitor (SQ14225) in hypertensive patients, Clin Sci Mol Med., 55, 453

10.1042/cs057421s

10.1056/NEJM197907053010103

10.1016/S0140-6736(80)90853-3

10.1001/jama.1980.03310040028020

10.1136/ard.34.5.416

10.1136/bmj.2.6049.1423

10.1161/01.HYP.2.2.236

10.1136/bmj.2.6148.1326

Thông tin
Thông tin xuất bản

Journal of Clinical Pharmacology

Tập 21 Số 11

508-516

Thông tin tác giả